Medicine. The need for a global HIV vaccine enterprise.

Journal article

A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

Authors: Klausner, R; Fauci, A; Corey, L; Nabel, G; Gayle, H

• Publication status: Published
• Journal: Science (New York, N.Y.)
• Volume: 300
• Issue: 5628
• Pages: 2036-2039
• Publication date: 2003-06-01
• DOI: 10.1126/science.1086916
• EISSN: 1095-9203
• ISSN: 0036-8075
• Language: English
• Keywords: Academies and Institutes; Drug Evaluation, Preclinical; Drug Industry; World Health; AIDS Vaccines; Intellectual Property; Financial Support; HIV Infections; Clinical Trials as Topic; Vaccination; Biotechnology; International Cooperation; Public Sector; Private Sector; Public Policy; Research Support as Topic; Multicenter Studies as Topic; Humans; Drug Design; HIV-1